X
3.37
0.02 (0.60%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | X4 Pharmaceuticals, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 2.0 |
| 相对估值 | NA |
| 财务健康 | -5.0 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | 0.13 |
|
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 2.43% |
| 机构持股比例 | 55.70% |
该时间范围内无数据。
该时间范围内无数据。
投资组合